藿香正气治疗湿热型特应性皮炎的随机双盲试验方案
本研究为双盲、多中心、随机对照试验,比较藿香正气口服液与安慰剂治疗伴有湿证的特应性皮炎/湿疹患者的疗效与安全性。计划纳入218例患者,疗程4周、随访4周,主要结局为湿疹面积和严重程度指数(EASI)。
要点
- 藿香正气口服液治疗特应性皮炎/湿疹缺乏高级别证据,本试验旨在填补空白。
- 纳入标准包括中医湿证、BSA 1-10%、IGA 1-3、年龄18-70岁。
- 主要结局为EASI,次要结局包括瘙痒评分、IGA、BSA、Skindex-29和EQ-5D-5L。
核心结论
- 本试验旨在评估藿香正气口服液治疗特应性皮炎/湿疹在症状和皮损方面的疗效与可用性,并探讨其对生活质量的影响。
研究设计与样本
- 双盲、多中心、随机对照试验,比较藿香正气与安慰剂,包含4周治疗和4周随访。
- 计划从中国7家医院随机分配218名参与者至藿香正气组和安慰剂组。
- 纳入标准为诊断为AD、符合中医湿证、BSA 1-10%、IGA 1-3、年龄18-70岁并签署知情同意书。
- 分析将采用意向性治疗和符合方案集原则。
关键数值与推荐
- 主要结局为湿疹面积和严重程度指数(EASI)。
- 次要结局包括数值瘙痒评分量表、IGA、BSA、Skindex-29和EQ-5D-5L评分,从基线至治疗结束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a complex, common inflammatory skin disease. The Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been a common dermatosis treatment in China for many years, but there is no high-level evidence for its effect on AD/eczema. The aim of this trial is to examine the efficacy and safety of HXZQ treating AD/eczema patients. METHODS: This is a double-blind, multi-center, randomized controlled trial comparing HXZQ to a placebo. It will consist of 4 weeks' treatment and 4 weeks of follow-up. A total of 218 participants will be randomly allocated into two groups-an HXZQ group and a placebo group, from 7 hospitals in China. Patients diagnosed with AD will be enrolled if they are in accordance with CM dampness pattern, have body surface area (BSA) of 1-10%, have investigator's global assessment (IGA) of 1-3, have age between 18 and 70 years, and provide signed informed consent. The Eczema Area and Severity Index (EASI) is the primary outcome. The secondary outcomes are the numerical itch rating scale, IGA, BSA, Skindex-29, and EQ-5D-5L score, from baseline to the end of the treatment. Analysis will be on intention-to-treat and per-protocol subject analysis principles. DISCUSSION: The goal of this trial is to evaluate the efficacy and availability of HXZQ oral liquid in treating AD/eczema in terms of symptoms and eczematous lesions. It will also address whether it has positive effect on QoL. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( http://www.chictr.org.cn/index.aspx ): Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a double-blinded randomized controlled trial, ChiCTR1900026700 . Registered on 19 October 2019.
引用
- Xuan M, Guo X, Li H, et al. The Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a study protocol for a double-blinded randomized controlled trial. Trials. 2021. PMID: 33468222. doi:10.1186/s13063-020-05014-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。